Piramal Healthcare, a well established arm of Piramal group is a name to cherish in the Pharmaceutical Industry today. In 1988, the Group decided to foray into the health care space with a move that was contrarian at that time, as most pharmaceutical players were exiting India due to the existing business climate. It has been 25 years, and they have established themselves as one of the most recognizable and respected names in the pharmaceuticals industry.
Today, they are manufacturing bases across India, UK, Scotland, USA and Canada through subsidiaries. Their critical care products are available in the emergency rooms of hospitals across the globe and products are available in over 100 countries. Presently they are third largest player in the global Inhalation Anesthesia (IA) market, and the only company in the world with a complete product portfolio of Inhalation Anesthetics drugs.
Through the years, Piramal Healthcare have partnered with the largest and most reputed organizations in the global pharmaceuticals industry to expand their product offering and deliver the best innovations to their customers. The ‘UN Conference on Trade and Development’s World Investment Report 2011’ ranks them among the top 5 in the world.
Piramal Pharma Solutions
A Contract Development and Manufacturing Organization (CDMO), Piramal Pharma Solutions offers end-to-end services required to bring a drug to the market place faster. They offer Pharmaceutical Development and Manufacturing solutions through collaborative partnership models and work with customers throughout the drug life cycle. Piramal Pharma Solutions is an key business division of Piramal Healthcare.
They have created a vast network of Development and Manufacturing facilities located in North America, Europe and Asia that offers a multitude of services covering the entire drug life cycle, from Drug Discovery & Development to Commercial Manufacturing of off-patent Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). Their capability as an integrated service provider & experience with various technologies enables them to serve Innovator and Generic companies worldwide.
Their Development centers & Manufacturing sites have accreditations from regulatory bodies in US, Europe & Japan. With a pool of 450 scientists, including 100 Ph.d’s across the Globe they are committed to Research & Development programs. They also offer specialized services such as Antibody Drug Conjugation and are well versed in technologies such as Bio-catalysis.
At Piramal Solutions, they are moving towards becoming a ‘Customer Centric’ organization by focusing on the “Pulse of the Customer”. They are evaluating various ways to improve their internal processes, communications, and program management in order to improve delivery commitments and service levels.
The division very well features among the top 10 contract drug manufacturers in the world as per report released by UN Conference on Trade and Development and recently in March 2014 they also bagged awards for “Quality” and “Reliability” in the CRO/CMO by Life Science Leaders.
“Shaped by our past and collective experience, we determine how we engage with others, what we identify with and what we love and value.”
Piramal’s Core values
Core values of Knowledge, Action and Care have been an integral part of Piramal Group. These values represent their deeply held beliefs and define the individual as well as organizational levels.
They truly encourage a deep understanding of these core values and believe in institutionalizing them across entire organization so as to build a distinctive Piramal culture.
The Piramal Group
A diversified conglomerate with operations in over 30 countries and brand-presence across 100 markets around the world, since the late 1980s, the Piramal Group has evolved from a textile-centric business to a diversified organization, which operates across sectors such as healthcare, life sciences, healthcare information management, financial services, specialty glass packaging and real estate.
As a Group, they have consistently identified opportunities ahead of the curve, even when market situations suggest the opposite. They invested in the domestic formulations business when others were focused on growing international generics. Their persistence paid off when a deal with Abbott in 2010 business valued at USD 3.72 billion, an unprecedented 9x sales and 30x EBITDA.
Over the past two decades, the Piramal Group has consistently focused on growth and today is ranked amongst the leading business conglomerates in India. The approach has been both organic and inorganic growth. We have built solid global partnerships to augment our presence in certain markets and continue to focus on core businesses by consistently investing in them.
Meet the Key Executive
Vivek Sharma, CEO, Pharma Solutions, Piramal Enterprises – Vivek heads Pharma Solutions at Piramal Enterprises Ltd. Carrying over 20 years of Global Management experience, he is a Chartered Accountant from India, a qualified CPA and also a Masters in International Business from Thunderbird School of Global Management. Prior to his role at Pharma Solutions, Piramal Enterprises, he worked with THL Partners as Managing Director, a Boston based private equity firm, where he was responsible for working with THL’s Portfolio companies to identify value creation opportunities and partner with the leadership of these companies for execution of growth/restructuring and cost optimization initiatives.
Benchmark Electronics will develop Qualcomm’s biometric patches to monitor vital signs and track patients